NAUT NAUTILUS BIOTECHNOLOGY INC

Nautilus Biotechnology to Participate in the 43rd Annual Cowen Health Care Conference

Nautilus Biotechnology to Participate in the 43rd Annual Cowen Health Care Conference

SEATTLE, Feb. 21, 2023 (GLOBE NEWSWIRE) -- Nautilus Biotechnology, Inc. (NASDAQ: NAUT; or “Nautilus”), a company pioneering a single-molecule protein analysis platform, today announced the company will be participating in the upcoming 43rd Annual Cowen Health Care Conference.

Nautilus’ management is scheduled to participate in a fireside chat on Monday, March 6th at 11:50 a.m. Pacific Time / 2:50 p.m. Eastern Time. Interested parties may access a live and archived webcast of the presentation on the company’s website on the “Investors” section of the company website at: .

About Nautilus Biotechnology, Inc.

With its corporate headquarters in Seattle and its research and development headquarters in the San Francisco Bay Area, Nautilus is a development stage life sciences company creating a platform technology for quantifying and unlocking the complexity of the proteome. Nautilus’ mission is to transform the field of proteomics by democratizing access to the proteome and enabling fundamental advancements across human health and medicine. To learn more about Nautilus, visit .

Media Contact

Investor Contact



EN
21/02/2023

Underlying

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on NAUTILUS BIOTECHNOLOGY INC

 PRESS RELEASE

Nautilus Biotechnology Reports Successful Installation and Testing of ...

Nautilus Biotechnology Reports Successful Installation and Testing of its First Field Evaluation Unit at the Buck Institute for Research on Aging • Buck Institute’s deployment of Nautilus’ instrument generates tau proteoform data, providing external validation of the company’s next-generation single-molecule proteomics platform • Joint research results show high reproducibility across sites and insight into novel tau biology, signaling a fundamental shift in how proteomics technology can advance human health and longevity • Data presentation at the 2025 HUPO World Congress seminar “Redefini...

 PRESS RELEASE

Nautilus Biotechnology Reports Third Quarter 2025 Financial Results

Nautilus Biotechnology Reports Third Quarter 2025 Financial Results SEATTLE, Oct. 28, 2025 (GLOBE NEWSWIRE) -- Nautilus Biotechnology, Inc. (NASDAQ: NAUT; or “Nautilus”), a company pioneering a single-molecule proteome analysis platform, today reported financial results for the third quarter ended September 30, 2025. Third Quarter 2025 Business Highlights Continued progress was made in processing Tau proteoform samples from collaborators in support of our goals of product validation and growing our publications. We expect to share this data at the upcoming World HUPO conference.Further ...

 PRESS RELEASE

Nautilus Biotechnology to Announce Third Quarter 2025 Financial Result...

Nautilus Biotechnology to Announce Third Quarter 2025 Financial Results on October 28, 2025 SEATTLE, Oct. 07, 2025 (GLOBE NEWSWIRE) -- Nautilus Biotechnology, Inc. (NASDAQ: NAUT; or “Nautilus”), a company pioneering a single-molecule protein analysis platform, today announced it will report financial results for the third quarter 2025 before market open on Tuesday, October 28, 2025. The company’s management will webcast a corresponding conference call beginning at 5:30 a.m. Pacific Time / 8:30 a.m. Eastern Time to discuss its results, business developments, and outlook. Live audio of the...

Jonathan Moreland
  • Jonathan Moreland

InsiderInsights Weekly Report: September 13, 2025

InsiderInsights Ratings of Companies with Open-Market Form 4 Purchases; Sales Filed at the SEC on the date above. We separate the real investment intelligence from the noise. Saving you time, and improving your research process

ResearchPool Subscriptions

Get the most out of your insights

Get in touch